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The self-assembly of proteins into supra-molecular structures and machinery underpins biologi-
cal activity in living systems. Misassembled, misfolded and aggregated protein structures can, by
contrast, have deleterious activity and such species are at the origin of a number of disease states
ranging from cancer to neurodegenerative disorders. In particular, the formation of highly ordered
protein aggregates, amyloid fibrils, from normally soluble peptides and proteins, is the common
pathological hallmark of a range a group of over fifty protein misfolding disorders. Because of the
critical role of the process in the aetiology of such disorders, as well as the quest to understand
the basic principles of protein folding and misfolding, the amyloid phenomenon has become a
central area of modern biomedical research. Advances in our knowledge of the physical prop-
erties of amyloid systems have, however, also highlighted the potential of amyloid structures in
the context of materials science. In this review, we explore how microfluidic approaches can be
used to study aspects of amyloid assembly and behaviour that are challenging to probe under
bulk solution conditions. We discuss the use of volume confinement to probe very early events
in the amyloid formation process. In addition, the well-defined fluid flow properties within chan-
nels with dimensions on the micron scale can be exploited to measure the physical properties of
protein aggregates, such as their sizes and charges, to shed light on the physical and chemical
parameters defining amyloid species. Moreover, the molecular species formed during aggregation
reactions have physical dimensions spanning at least three orders of magnitude, and microfluidic
techniques are well suited to work with analytes of such disparate dimensions. Furthermore, the
flexibility of the design of microfluidic devices lends itself to adaptable experimental setups, includ-
ing the study of protein self-assembly within living cells. Finally, we highlight the salient features
of microfluidic experiments that facilitate probing complex biological systems, and discuss their
use in the exploration of amyloid as a class of functional material.
Introduction
The self-assembly of proteins to form amyloid aggregates is the
hallmark of a range of protein misfolding diseases including neu-
rodegenerative disorders, non-neuropathic conditions and sys-
temic amyloidoses.1–6 In recent years, much interdisciplinary re-
search has aimed at developing an understanding of the micro-
scopic processes involved in amyloid formation. In this context,
the properties of the aggregates formed by a number of specific
proteins have been characterised.7–19 Experimental and compu-
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tational approaches have been employed in studies of the bind-
ing and the effect of potential aggregation inhibitors aggregation,
ranging from small molecules to proteins have been performed,
both to understand the fundamentals principles underlying the
process of aggregation, and to devise potential therapeutic inter-
vention strategies.20–32
In recent years, high-resolution techniques from structural bi-
ology have been applied to the investigation of amyloid aggre-
gates, revealing a detailed picture of the fibrillar architecture and
highlighting the generic features of amyloid aggregates formed
by proteins with a wide range of different native state struc-
tures, functions, and amino acid sequences.1,7–9,33–35 Thus, the
characteristic cross-β structure of amyloid fibrils has been shown
to be stabilised by non-covalent interactions between the pep-
tide backbones of the constituent polypeptide chains, and their
generic architecture does not depend on their specific amino
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acid sequences. The amyloid structure represents a free energy
minimum in the energy landscapes of many proteins, and, once
formed, aggregates can therefore be highly persistent.36 The self-
assembly of peptides and proteins to form amyloid aggregates
results in supramolecular structures that are not amenable to the
fast and reversible assembly and regulation, which is necessary
for functional intracellular self-assembly processes, such as the
reversible polymerisation of cytoskeletal proteins associated with
the mobility of cells. The observation that under given solution
conditions, proteins with diverse native structures and functions
can be induced to form amyloid aggregates, even for proteins not
associated with amyloid formation in vivo, led to the hypothesis
of amyloid as a generic protein structure.1 Moreover, there are
now multiple examples of forms of amyloid structures involved
in functional roles in systems as diverse as the extracellular ma-
trix of E. coli, fungal prions, spider silk, melanin synthesis and
hormone storage.37–41
Studies of the material properties of amyloid structures have
highlighted their potential as biocompatible materials for a wide
range of uses.24,42–47 Several reductionist model systems have
been designed for the study of amyloid formation, including the
use of short peptide sequences derived from amyloidogenic pro-
teins. In the case of the amyloid-β (Aβ) peptides, which are found
as amyloid aggregates in Alzheimer’s disease, this approach has
eventually led to the reduction of the model peptide to just two
amino acids, diphenylalanine (FF), thus pushing the boundary
between protein aggregation and crystal formation.48,49
Microfluidic methods can advance the study of amyloid forma-
tion, both as a platform for improved assays and in the develop-
ment of strategies to address questions which have hitherto been
challenging to access using bulk solution methods. Specifically,
the confinement of fluid flow into small channels and the result-
ing laminar flow profile enables precise modelling and control
of the fluid flow and thereby quantitative characterisation of the
analytes present.50 This feature is a key factor in a number of
strategies aiming to probe the physical properties and morpholo-
gies of amyloid aggregates formed under flow.43,51,52 Moreover,
in order to enhance the number of species that can be analysed on
chip, separation modules have been combined to achieve a multi-
dimensional sample analysis.53–55 As an example, isoelectric fo-
cusing followed by capillary electrophoresis achieves narrow pre-
concentrated analyte bands for downstream analysis.55–57
Chip-based applications include the determination of size, elec-
trophoretic mobility, and charge of a given system, without
the need for calibration against the behaviour of a reference
molecule.58–62 Changes to the size or charge of sample molecules
upon complex formation can be explored to probe non-covalent
protein-protein interactions and protein-ligand binding.59,60,63,64
These microfluidic strategies can be, and have been, applied to
characterise the properties of amyloid structures and their inter-
actions with chemical compounds or other proteins.60,62,63,65
Microfluidic methods have been applied succesfully to the high-
throughput generation of microdroplets with highly uniform vol-
umes. Such microdroplets present another promising approach
to the further study of amyloid systems. The use of microdroplets
allows a large number of independent reactions to be monitored
simultaneously in volumes which are several orders of magnitude
smaller than has been usual in bulk assays.66–68 In addition to
parallelised screening, volume confinement can be exploited to
observe stochastic and often rare events taking place as part of
the amyloid formation process and obtain statistic information on
their occurrence.69 Indeed, the amyloid formation process is gov-
erned by a series of microscopic steps, such as primary nucleation,
elongation, fragmentation, and aggregate induced secondary nu-
cleation, which vary in relative importance between different sys-
tems with the more dominant steps masking rarer ones in non-
compartmentalised bulk scale assays. Furthermore, inside indi-
vidual droplets the spatial propagation and distribution of amy-
loid species can be monitored as a function of time.69,70 The in-
teraction between analytes and microdroplet interfaces can be ex-
plored to characterise the physical and mechanical properties of
species ranging from individual proteins to entire cells.43,47,70,71
The molecular and supramolecular species found during the
conversion from soluble precursor protein to amyloid aggregates
span dimensions from the Ångström to the micrometre scale. Mi-
crofluidic strategies have found applications in research at many
levels of amyloid formation and behaviour as they can easily ac-
commodate such a wide range of analyte sizes.52,69,72,73 The
sample volumes required for experiments within channels with
dimensions on the micron scale are greatly reduced compared to
experiments in bulk solution, an important consideration in cases
where the available sample material is limited, for instance in the
case of samples derived from in vivo sources.70 Furthermore, the
availability of highly sensitive optical detection methods enables
samples to be studied at the single-molecule level,74 a feature,
that enables analytes to be studied at low concentrations, for ex-
ample allowing amyloid precursor proteins to be characterised
at physiological concentrations. The ability to study samples at
the single-molecule level also allows small populations within an
ensemble to be probed. Here, we explore current microfluidic
strategies that can provide improvements over conventional as-
says in bulk solution in terms of assay times and throughput.75,76
We review approaches which allow the study of rare events in
protein aggregation to generate an understanding of the underly-
ing protein-protein interactions, while extending these methods
for performing high-throughput experiments. These approaches,
in turn, give rise to microfluidic means of exploring more com-
plex phenomena, such as the manner in which proteins interact
to form aggregates in cells and tissues, while allowing control of
such interactions in the development of new protein-based mate-
rials for future applications.
The physical properties of amyloid aggre-
gates
The majority of the measurement techniques currently in use for
the characterisation of individual proteins and the species found
on the amyloid formation pathway are bulky and operate over
long timescales. Furthermore, such characterisation measure-
ments are typically performed either in the gas phase (e.g. mass
spectrometry) or on chromatography columns which employ sup-
port matrices in order to limit the diffusion of analyte molecules
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and allow their controlled movement. This is in contrast to
the well-defined non-turbulent fluid flow profiles characteristic
of small length scales, such as micron scale channels, which can
keep analyte molecules localised even without the involvement of
any external support medium. As such, not only can microscale
channels be used to characterise the chemical and physical prop-
erties of aggregated species using only very small sample and
reagent volumes, the analysis can be carried out on orders of
magnitude shorter timescales than with conventional approaches
where the involvement of the support matrix restricts fast move-
ment of individual molecules. These features have enabled both
the size and electrophoretic properties of amyloid species to be
determined under steady state flow conditions, Fig. 1. Notably,
the laminar flow enables the sample diffusion and migration in
an electric field to be analysed in a quantitative manner, yielding
absolute values for physical parameters, which can be compared
between solution conditions.60,64,65
In addition, the ability to perform analysis directly in aque-
ous environments lends itself effectively to probing the physi-
cal properties of the amyloid aggregates, in particular as the
species formed on aggregation pathways are transient and com-
monly held together by reversible non-covalent interactions.
For instance, the species formed during the aggregation of α-
synuclein, a protein whose aggregation is associated with the ae-
tiology of Parkinson’s disease, have been characterised using ther-
mophoretic and electrophoretic approaches, Fig. 1b.65 By deter-
mining the electrophoretic and thermophoretic mobilities of the
monomeric, oligomeric and fibrillar forms of α-synuclein, it was
found that these parameters could be employed to differentiate
between the species of the aggregation reaction. This approach
could in the future enable separation of the reaction mixture into
the individual components to then further characterise the physi-
cal properties of the different species either directly on chip or via
an off-chip analysis approaches, such as atomic force microscopy
or mass spectrometry.77,78
The process of amyloid formation in confined
volumes
The presence of an air-water interface can be eliminated by ob-
serving the amyloid formation process in microdroplets, enabling
surface effects to be studied in a controlled manner.70 To probe
the effect of different liquid-liquid interfaces, a plug-based mi-
crofluidic approach modified with teflon tubing was used for the
study of Aβ40 aggregation, Fig. 2a.70 Once Aβ40 is encapsulated
inside a plug, it is protected from the surfaces of microchannels
by a layer of fluorocarbon oil, and it is the surface chemistry of
the aqueous/fluorous interface that starts affecting the aggrega-
tion process. In plugs with fluorocarbon/water interfaces, an in-
crease in the fluorescence signal of the labelled Aβ40 peptide at
the plug edges was observed, indicating adsorption of the pep-
tide to the interface. In contrast, in plugs with an amphiphilic
fluorinated surfactant/water interface, the fluorescence signal of
the labelled peptide remained evenly distributed, indicating that
the amphiphilic surfactant prevents Aβ40 adsorption to the inter-
face. These findings further uncovered a general driving force,
originating from confinement, which, together with biological
quality control mechanisms, helps proteins remain soluble and
therefore functional in nature.70 The importance of interfaces
and lipid membranes in particular has been illustrated in bulk so-
lution studies, microfluidics provide an ideal platform for further
studies of the effects of interfaces on amyloid formation.79
During the amyloid formation process, the products of rel-
atively rare primary nucleation events are amplified through
elongation and secondary events, which include fragmentation
and surface-induced nucleation.80 Thus, once initial nucleation
events have occurred, the kinetics of the formation of amyloid
species in a sample are often dominated by such processes.81 Pri-
mary nucleation events are therefore challenging to detect and
quantify in bulk solution assays. The compartmentalisation of
a sample solution into microdroplets enables the propagation of
the aggregation reaction to be monitored from single nucleation
events, and permits the tracking of both the spatial and temporal
evolution of such events, Fig. 2b.69 Through this approach, the
specific secondary processes dominating amyloid formation by in-
sulin could further be identified. The study highlighted the de-
pendence of the aggregation lag time on the system size.69,82,83
The picolitre volumes of microdroplets represent a closer approx-
imation of cellular dimensions than the tens of microlitres used in
plate reader assays, and can help to explain the relative stability
of proteins in confined cellular compartments.84
The process of amyloid formation under flow
The well-defined flow properties within microfluidic channels can
be used to address additional questions relative to measurements
in bulk solution. For example, performing experiments under
flow enables the amyloid formation process to be probed under a
different set of mass transport constraints compared to bulk mea-
surements or microtiter plate assays. Specifically, the effect of
mass transport on the rate of the amyloid formation reaction has
been investigated for insulin fibril formation, Fig. 3a.51,85 The
results showed that for channels coated with insulin fibril seeds,
the amyloid formation process was substantially accelerated by
an increase in the flow of protein monomer in the channels. This
finding highlights the importance of performing measurements
on amyloid formation under well-controlled mass transport con-
straints for the purpose of reliable comparison.51,85
The introduction of flow has also enables the effect of fluid
shear stress on aggregate morphology to be probed. For exam-
ple, it has been shown that the morphology of insulin aggregates
can be affected when the amyloid formation process takes place
in a flow field in a confined microfluidic channel, rather than in
bulk solution. Specifically, structures with fibre-like morphology
have shown to dominate when the fibrils are formed in channels
where the flow rates are high, while low flow rates lead prefer-
entially to the formation of spherical aggregates or spherulites.52
Such an ability to exert control over the morphology of the amy-
loid structures by a simple combination of volume confinement
and movement of fluid could be especially valuable for the appli-
cations that employ amyloid fibrils for functional purposes.
Investigating reactions under steady state flow conditions al-
lows multiple processes to be spatially decoupled from one an-
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Fig. 1 The precise control over fluid flow at micron scale enables quantitative characterisation of biomolecules and their complexes on chip.
(a) Schematic rendering of a microfluidic device with the different scales of species involved in amyloid formation: monomers; oligomers 16 and
fibrils. 34 Microfluidic methods can be used to explore the interactions of these species with small molecules, with each other, and with macromolecules
such as chaperones, as well as with fibril networks and gels. 45 The laminar flow within microfluidic channels enable analytes to be separated and
characterised based on their diffusion coefficients. 60 (b) Integrating electric fields with microfluidic channels has enabled physical characterisation of
individual proteins, protein oligomers and amyloid fibrils. Here, solid metal wall electrodes were automatically aligned with the fluidic channels by
micropillar arrays. An electric field was generated perpendicularly to the direction of flow and the electrophoretic mobility of the sample was
quantified. 58,64 (c) Microfluidic diffusional sizing has been used to determine the hydrodynamic radii of individual biomolecules in solution. A stream of
protein molecules was flanked by buffer streams, and the diffusion of the protein molecules into the adjacent fluid flows was observed. The acquired
data can be used to extract the concentrations of individual molecules and their complexes. 60 (d) Integrating high electric fields with microscale
channels has enabled rapid fractionation of proteins and their complexes. This approach allows real-time probing of the interactions between the
transient species formed on the aggregation pathway and external molecules, such as potential therapeutic agents interfering with these species. 62
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Fig. 2 Exploring the process of amyloid formation under volume
confinement. (a) Encapsulation and aggregation of Aβ40 in plugs with
controlled interfaces compared with plugs without interfacial control and
with well plates. Left - schematic of the microfluidic droplet generating
device. Fluorescence images of HiLyte-488-labelled Aβ40 in plugs with
fluorocarbon/water (middle), showing how the protein is enriched at the
interface, and Rf-OEG3/water interface (right), displaying an even
protein distribution. 70 (b) Microdroplets incubated within microfluidic
storage array channels enabled single nucleation events and
proliferation of the aggregation reaction to be observed. 69
other while keeping the whole process integrated on a single chip.
Specifically in the context of amyloid formation, the key processes
involved, and to be maintained as isolated events, are the pro-
tein aggregation step and the aggregate labelling step employed
for probing the process through optical means. Indeed, many of
the frequently used probes for monitoring the process of amy-
loid formation, such as Congo Red, Thioflavin S and Thioflavin T,
have been shown in some situations to influence self-assembly
processes, and as such, may preclude the reliable extraction of
quantitative information regarding the concentration of aggre-
gated material present.86–88
When protein self-assembly is studied in the presence of small
molecules with high affinity for the aggregates, a further risk of
interference between the amyloid forming species, the inhibitor
molecules and the probe molecules is introduced. To illustrate
this consideration, some of the very effective molecules observed
to inhibit protein aggregation have structures that are modelled
on amyloidophilic dyes.22,89,90 The possibility of interference by
probe molecules is effectively reduced by using a flow-based mi-
crofluidic platform where the aggregation process takes place in
a label-free environment, whilst the detection downstream still
benefits from the high sensitivity afforded by label-based detec-
tion, Fig. 3b.73 This feature is in contrast to conventional ap-
proaches for monitoring fibril formation, where the aggregation
process normally occurs in the presence of labels. In this study
the control over fluid flow at small length scales enabled the mix-
ing between the aggregating protein and the probe molecules to
occur in a fast and non-disruptive manner. Because of the small
scale of the channels, low molecular weight probe molecules can
diffuse into the protein stream within a few seconds, allowing
rapid detection of the extent of aggregation immediately follow-
ing their introduction, without inducing any potentially disrup-
tive shear stresses that would be required for rapid mixing on
larger scales.73
Finally, the flow through microfluidic channels can be used to
accelerate the incidence rate of sample molecules passing through
a detection area, thus overcoming the limits that are otherwise
set by sample diffusion. This feature has been put to elegant use
in the context of performing measurements on the amyloid for-
mation process at the single molecule level, Fig. 3c.74,91 By using
microfluidic channels and performing a series of sample dilutions,
single molecule data on protein aggregation could be acquired
over 100 times faster than in conventional confocal measure-
ments, that do not take place under flow, increasing the achiev-
able time resolution from hours to minutes. This enhanced reso-
lution opens up the possibility of probing aggregation processes
on time scales that are significantly more relevant to understand-
ing in detail the kinetics of the microscopic processes of protein
self-assembly.
Interactions between amyloid structures and
other molecules
In addition to the characterisation of the physical properties of
the species formed during a protein self-assembly process, there
is great interest in developing methods that would enable stud-
ies to be made of the chemical properties of the species formed
during protein self-assembly, in particular, their interactions with
one another, with potential binding partners, and with aggrega-
tion inhibitors. It has recently been illustrated, for example, that
the ability to model precisely the molecular diffusion of individ-
ual molecules in microscale channels can be used to determine
accurately and rapidly the size of particles, such as proteins in
free solution, Fig. 1c.60 The diffusion of sample molecules into
co-flowing carrier medium was monitored as a function of resi-
dence time in the analysis channel. Analysis of the spatial sample
distribution thus enabled the diffusion coefficient of the analyte
molecule to be extracted. By deconvoluting average signals into
those originating from the individual species, this method was
shown to facilitate the sizing of both individual biomolecules and
mixtures of biomolecules. The approach was used to determine
the binding constant between α-synuclein and its single domain
antibody fragment directly in a cell lysate. As part of this study,
it was observed that the aggregation-suppressing antibody could
bind to both the monomeric and the aggregated forms of the pro-
tein - a finding that is in agreement with the available structural
data, as the antibody binding epitope is known to be located at
the C-terminus of α-synuclein, in a part of the sequence that is
not incorporated into the core of the aggregated species.60
The highly reproducible prototyping of microfluidic chips via
soft-lithography approaches, and the tight control that can be
exerted over fluid flow in micron scale channels, can yield
highly quantitative data on the physical parameters of individual
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Fig. 3 The use of microfluidics to monitor the process of amyloid
formation. (a) The growth of surface-tethered insulin fibrils within
microfluidic channels. Bright field image of the microchannels (left).
Fluorescence image of the microchannels and fluorescence intensity
profiles (right). 85 (b) Microfluidic approaches have been employed to
automate the measurements of protein aggregation while enabling fibril
formation to occur in the absence of external molecules, such as dyes
used to probe the process (left). Eliminating manual fluid handling steps
allows the aggregation to be studied at a higher throughput than
conventional manual measurements (right). 73 (c) A flow-based
single-molecule detection microfluidic system which in contrast to
conventional single molecule confocal measurements on protein
aggregation can achieve measurement times of minutes rather than
hours. 74
molecules. For example, tracking the electrophoretic mobility of
a complex between creatine kinase and calmodulin was achieved
by titrating the kinase into a calmodulin solution of a fixed con-
centration.64 These data allowed the construction of a binding
curve for the interaction between the two proteins and ultimately,
determination of the equilibrium parameters for the interaction.
Importantly, the latter approach indicates the strength of the in-
teraction directly in free solution, free of the biases, that can be in-
troduced by conventional surface-based techniques into the mea-
surements on binding interactions. In the future, such a platform
could be applied with the aim of determining the equilibrium pa-
rameters for the species that are formed on the aggregation path-
way and the affinity for their binding partners.
Integration of strong electric fields with microfluidic channels
has also enabled the development of an electrophoresis-based
separation technique that can be used to identify interactions
between transient species on the aggregation pathway and the
molecules that bind to such species.62 Specifically, using such
a rapid fractionation platform the interaction between Aβ fib-
rils and the Brichos domain chaperone was detected and the free
chaperone separated from the chaperone-fibril complex in a cou-
ple of seconds and directly in free solution without the involve-
ment of a support matrix, Fig. 1d. By binding to Aβ fibrils, the
Brichos molecules can potentially inhibit further secondary nu-
cleation events from occurring on the surfaces of the fibrils.27
Detecting such interactions between specific transient species on
the aggregation pathway and potential inhibitor molecules pro-
vides key insights into the specific steps of the aggregation path-
way selected inhibitor molecules intervene with, and through this
approach facilitates rational therapeutic design strategies.92
Another on-chip study has specifically focused on detecting the
presence of early events on the aggregation pathway. The analy-
sis employed a two-dimensional separation approach involving
a combination of isoelectric focusing and capillary zone elec-
trophoresis.93 The combined platform allowed the time-course
of α-synuclein aggregation to be studied and provided a strategy
for real-time detection of early and intermediate species on the
aggregation pathway. As part of the study it was shown that the
chip could be used to analyse the effect of small molecules on the
aggregate formation process and could as such serve as a platform
for screening for potential aggregation inhibitors.
Last but not least, the ability to exert control over fluid flow
at small length scales and thereby analyse molecules in their
label-free state has been explored. It has been demonstrated that
the physical parameters of biomolecules and biomolecular com-
plexes can be accurately probed by quantitatively labelling them
after the process of interest has incurred. This order of events is
achieved through the sequential arrangement of the separation,
labelling, and detection elements on chip. Such post-process la-
belling ensured that the physical properties determined in this
way describe the unlabelled rather than the labelled state of the
molecule or the complex.63 Using this strategy the interactions
could be described between α-synuclein monomers and nanobod-
ies in their label-free states. Such microfluidic devices provide
effective platforms for probing biomolecular processes and inter-
actions in a label-free manner while ensuring that the molecules
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of interest can in principle be analysed at physiologically relevant
concentrations.
Chemo-mechanical force transduction
In biological systems, the generation of mechanical force is cen-
tral to a wide range of phenomena, including cellular movement
and traction to surfaces. Movement, for example, is controlled
through the self-assembly of cytoskeletal proteins that enables
extension and contraction of cells.94,95 In this context, mechan-
otransduction has been a topic of considerable interest, ever since
early studies demonstrated a link between a mechanical force and
the corresponding biological response. Mechanotransduction is a
process which involves mechanical stimulation that elicits a re-
sponse from the cell, which can itself alter the intrinsic mechan-
ical properties of the cell and can change the cellular microenvi-
ronment. Recent studies using microfluidic techniques have al-
lowed precise control to be exerted over the multiple factors that
influence cellular responses.96
In addition to the involvement of native proteins in force pro-
duction in cells, tissues and organisms, force generation by the
effect of aberrant self-assembly is of much interest in the context
of amyloid formation. The capacity for high power force gener-
ation in this context is not related to their function in cell motil-
ity.95,97 The forces emerging from the self-assembly of native pro-
teins have been studied in detail, yet the potential for force gen-
eration by aberrant protein polymerisation has only recently been
explored by utilising microfluidics based approaches, Fig. 4.
The self-assembly of biologically relevant components is also
an attractive route towards force generation in an active mate-
rials, since such processes can take place under ambient condi-
tions, with no, or minimal, requirements for external energy in-
put. In such systems, force generation corresponds to the release
of free energy due to addition of monomers and is best expressed
in terms of the energy density. In order for these systems to gen-
erate a significant amount of force, the molecular building blocks
must be arranged in such a way that there is some directionality in
the system. In particular, this aim has been achieved by harness-
ing microfluidic techniques to measure the forces released by the
growth of amyloid fibrils formed by insulin and lysozyme. It was
demonstrated that such fibrils are capable of unleashing mechan-
ical forces on the piconewton scale for individual filaments.43
By trapping insulin protein aggregates between microcantilevers
within a microfluidic channel, under a continuous flow of pre-
cursor protein, a precise control over the growth of the fibrils was
achieved, Fig. 4a. The level of force measured for amyloid growth
in both insulin and lysozyme systems was found to be compara-
ble to those observed for actin and tubulin, systems that have
evolved to generate force as part of their native functions and,
unlike amyloid growth, rely on the input of external energy in the
form of nucleotide triphosphate hydrolysis for maximum force
generation. The force generated by amyloid aggregate growth
would be sufficient to deform materials with properties similar
to cells. This aspect of amyloid formation could therefore be a
contributing factor to the pathology of systemic amyloidoses.
Recently, a minimalist model system for amyloid formation,
FF, was investigated and found to generate forces of a similar
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Fig. 4 (a) Design of the microfluidic device used to study forces
produced through protein self-assembly. The pre-formed insulin
aggregate clusters were introduced into the device, and a continuous
supply of monomer was flowed through the channel (top). Schematic
diagram showing the introduction of preformed spherulites into the
microfluidic device, where they were trapped between microcantilevers
(middle). To monitor the cantilever deflection, time course images were
acquired through the glass slide at the bottom of the device (bottom)
exhibiting spherulite growth within the device. 43 (b) Comparison of the
chemo-mechanical transduction in FF nanotubes with energy (J cm−3)
and power (W cm−3) densities by synthetic actuator systems, biological
stimuli-responsive materials and biological self-assembly systems 47.
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order of magnitude to those of complex biological systems and
synthetic polymers.47 The ability of the FF molecules to self-
assemble into ordered tubular structures was reported over a
decade ago, yet, due to the highly dynamical nature of molecular-
level self-assembly phenomena, it has been challenging to achieve
forces for actuation on length scales exceeding that of the build-
ing blocks themselves.48 By employing a microfluidic platform
in which super-critical solutions of FF were encapsulated within
microdroplets, and could be triggered later to self-assemble by
evaporation, it was shown that linear FF assembly could gener-
ate forces that were sufficient to rupture water-in-oil double layer
interfaces. In this case, no large-scale actuation on sub-second
timescales was permitted, since the rate of energy release was
limited by the rate of FF self-assembly. However, this limitation
could be overcome by tailoring the geometry of the system to ac-
cumulate elastic energy through chemo-mechanical transduction,
followed by a rapid release as a result of an elastic instability.47
Such elastic instability could be further controlled through the
rate of solvent evaporation within the droplets, thus allowing the
regulation of the self-assembly kinetics and of the force generated
by the tube unbuckling. Moreover, this system was employed to
generate external work using an actuating self-assembly system,
as the energies released in the unbuckling events were sufficient
to displace physically neighbouring droplets. Through a compar-
ison of the results for the chemo-mechanical transduction of FF
tubular assemblies with values for the power generated by syn-
thetic actuators, biological self-assembly systems, as well as bi-
ological systems that exploit mechanical instabilities to release
stored energy, it has been shown that the energy and power den-
sities calculated for the energy released from the unbuckling of
a single nanotube when normalised to the volume of the nan-
otube, and the upper limit of actuation time provided by the FF
system exceeded those resulting from force generation by con-
ventional biological self-assembly, including actin polymerisation
Fig. 4b. Thus, at a fundamental level, the exploitation of elastic
instabilities has allowed the generation of a system which lever-
ages biomimetic self-assembly to generate power-densities that
are higher than those reported for biological self-assembly, and
similar to systems that were specifically designed during evolu-
tion to yield high energy release.
Through the combination of diverse microfluidic-based ap-
proaches with real-time imaging analysis and modelling, the
force generation and actuation by proteins and supra-molecular
polymers have been established as high power-density modes of
chemo-mechanical force transduction, opening up the possibil-
ity of using elastic instabilities for future applications in other
short peptide, protein, and synthetic polymer systems. Nucle-
ation, growth and phase transitions in biological and synthetic
self-assembling systems may elucidate the natural occurrence of
such phenomena in nature and in amyloid related diseases.
High-throughput assays
As a result of their rapidity and low consumption of reagents for
a given reaction, microfluidic devices are an attractive platform
for performing high throughput screens, for example to identify
inhibitors of amyloid formation. The majority of protein aggrega-
tion assays to date have been performed in multiwell plates where
the required volumes are orders of magnitude larger than those
of microfluidic channels or microdroplets, and this is therefore an
important area for the development of microfluidic techniques.
Miniaturised channels have been used successfully as individ-
ual compartments for probing the process of aggregation and
thus for exploring the inhibitory effects of drug candidates and
metal ions on the fibril formation process.51 The sample vol-
umes of the assay chambers in these experiments were around
0.1 µL. To achieve a further reduction in reagent consumption
and an increase in throughput, sub-nanolitre aqueous droplets
compartmentalised by an immiscible phase, such as an oil, can
be employed.66,68 For example, such an aqueous microdroplet-
based platform has been used to study the inhibitory effects of
Orange G on the aggregation of AcPHF6 tau-hexapeptide98 and
to track the aggregation of Aβ in the cerebrospinal fluid (CSF)
of mice.70 With the volume of the CSF in a single mouse being
only a few microlitres, the dramatically reduced volumes of mi-
crodroplets compared to microwell plates and the possibility of
performing repeated analysis on the CSF from the same animal
illustrate the effectiveness of microdroplet-based approaches on
monitoring the aggregation process in non-readily accessible bio-
logical fluids.
Compartmentalising bulk solutions between individual micro-
droplets and subsequently amplifying specific species in these
droplets forms the basis for precisely and accurately quantify-
ing the presence of specific species of interest. This approach
has been applied in the context of nucleic acid detection and
has led to the development of widely used technologies, such as
the digital polymerase chain reaction, which enables highly sensi-
tive detection of individual DNA strands.99,100 A similar approach
has recently shown to facilitate effectively the development of a
rapid and highly sensitive assay for the quantification of amyloid
propagons in protein solutions, Fig. 5a.101 The assay developed
in this study reached the ultimate sensitivity limit of detecting in-
sulin propagons down to a digital level, where a single aggregate
is detected. Its performance compared favourably with existing
and alternative assays in terms of its speed and sensitivity. Such
assays have the potential to be used to detect small amounts of
aggregates in biopharmaceutical preparations where the presence
of even the smallest traces of protein aggregates can lead to im-
mune responses.102
The extension of the microdroplet platform to applications that
require experiments to be performed under non-identical condi-
tions, such as the screening of molecular libraries of potential
aggregation inhibitors, has so far been limited by the rate of
translation from proof-of-concept to general use in a biological
context. Titrating the potential candidates into microdroplets at
different dilutions or testing mixtures of different candidates at
different ratios could be achieved to exploit already established
approaches, such as merging aqueous streams on chip before
emulsification or, alternatively, performing fusion steps after the
emulsification.103 A key challenge that still has to be addressed in
this context, involves establishing a strategy for uniquely labelling
each of the compounds in the library to enable the identification
of successful candidates after the high-throughput screening pro-
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cess. Possible approaches for addressing this challenge, and add
a unique identifier to act as a barcode for the different droplets,
have been reviewed in contexts beyond aggregation assays104 but
are likely to be equally applicable to the protein self-assembly
process. The identification labels have been proposed to include
dilution series of fluorophores, quantum dots or DNA-sequence
based barcoding libraries.67,104,105
Last but not least, in addition to the advantage of the re-
duced reagent consumption, high-throughput microfluidic assays
also enable the work flow of screening assays to be simplified
and automated. As an example, a common strategy for identi-
fying biomarkers, including those for the onset of neurodegen-
erative disorders, involves enzyme-linked immunosorbent assays
(ELISAs). ELISA typically requires multiple washing steps be-
tween each stage to remove unbound material from the samples
and to avoid non-specific interactions, and as such consume rel-
atively large quantities of the samples and reagents (e.g. 50-150
µL per condition). An elegant droplet-based magnetic bead im-
munoassay was recently demonstrated as an alternative to con-
ventional ELISAs. By connecting wells with microchannels, ana-
lytes attached to magnetic beads were transported between the
large droplets trapped in the wells, eliminating the need for the
washing steps involved in conventional bead based immunoas-
says and minimising the quantity of the sample required and the
reagents involved, Fig. 5c. This technique has been employed to
target oligomeric Aβ , which has been suggested as a biomarker
in the characterisation of Alzheimer’s disease.106
Amyloid formation in cells
Microfluidic devices have increasingly been used to separate
cells, and the accuracy and efficiency of recently developed sort-
ing methods are comparable to their macroscopic counterparts.
These advances have stimulated their use as novel strategies for
cell separation, which is an integral step to processes involved
in applications ranging from food production to environmental
monitoring, and the process used by pharmaceutical industry. A
variety of force fields have been implemented to generate mi-
crofluidic cell separation mechanisms, ranging from gravity to
hydrodynamic, electric, acoustic, optical and magnetic forces. In
particular, fluorescence and magnetic activated cell sorters use
external labels of the targeted or non-targeted cells to establish
specificity.111,112
Microfluidic compartments can also be used to encapsulate liv-
ing cells in order to probe in vivo systems. For example, mi-
croscale cultures of primary central nervous system (CNS) cells
have been integrated with micro-compartments and exposed to
different types of Aβ aggregates to mimic the environment in
Alzheimer’s disease, Fig. 6a. In four parallel experiments, the re-
sponse of the CNS cells to treatment with different drugs was ex-
amined and the compound FTY720 was suggested as a promising
candidate for preventing neudrogeneration after the cells have
been exposed to neurotoxic oligomeric forms of Aβ .107 Lab-on-
a-chip techniques may help to accelerate drug development by
providing alternatives to traditional cell-based methods. Thus,
biomimetic microsystems that reconstitute cell-to-cell communi-
cations are well suited for the development of models that mimic
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Fig. 5 High throughput microdroplet assays in studies of amyloid
systems. (a) Distributing a protein solution between multiple
microdroplets and tracking the rate at which aggregates are formed in
these droplets has enabled ultrasensitive assays for determining the
concentrations of individual propagons to be developed. The assay was
demonstrated to reach the ultimate sensitivity limit of detecting a single
propagon. 101 (b) The extension of the microdroplet platform to
applications that require parallellised experiments to be perfomed under
non-identical conditions, such as the screening of potential aggregation
inhibitors, has remained limited due to the lack of appropriate barcoding
strategies. One of the potential strategies for overcoming this limitation
and devising a barcoding strategy for identifying effective inhibitors
involves the use of multiple fluorophores in a dilution series, 105 with
promising alternatives including quantum dot and DNA sequence based
barcodes. 67,104 (c) By connecting individual microfluidic wells with
microchannels analytes attached to magnetic beads can be moved
between droplets trapped in individual wells, allowing multi-step
analysis, such as ELISA, to be simplified and automated while limiting
sample and reagent consumption. 106
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Fig. 6 Cell based assays utilising microfluidic techniques. (a) Illustration of the principle of operation via gravity-induced flow (top; CNS indicates the
chamber where primay cells are plated). Representative images of pure microglia cultures incubated with oligomeric (bottom left) and fibrillar (bottom
right) Aβ , fixed and immunostained with IBA1 (red) for microglia and 6E10 (green) for Aβ . 107 (b) Top- Microfluidic chambers connected through a
narrow channel were used to investigate interactions between neurons exposed to glutamate. 108 A similar approach was used to study the
internalisation and retrograde transport of tau aggregates in neurons 109. Transport of short (middle) and long fibrils (bottom) is shown in green within
axons (red). Magnified areas of the channel are shown at the bottom of each micrograph. (c) Right - a microfluidic chemotaxis platform models the
pathological Aβ environments in Alzheimer’s disease brains and provides surface-bound Aβ inside the central compartment, and gradients of soluble
Aβ between the central and annular compartments, along a migration channel. 110 The symmetric configuration enhances the microglia counting
during Aβ recruitment and the long and thin migration channels help to avoid counting errors due to spontaneous migration. Middle - induction of
microglial directional migration by gradients of Aβ42. Individual microglia migrate directionally along the gradient of sAβ42 monomers formed in
migration channels. Right - activation of directional motility can be discerned after 24 hours of exposure to gradients of sAβ42 monomers. 110
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more closely human tissue, with the additional advantage of us-
ing reduced amounts of cells and reagents, therefore decreasing
the impact on the use of animals or human tissue. Such chips
have the potential to form an easy-to-use alternative to standard
cell cultures, increasing the throughput and reproducibility in as-
sessment of toxicity and drug efficacy in living systems.
As microfluidic systems are increasingly applied in the inves-
tigation of biological phenomena and are increasingly utilised
as cell culture platforms, the properties of the materials used to
manufacture the devices, such as gas permeability, optical trans-
parency, and flexibility, must be considered in a biological con-
text.113 By exploiting these intrinsic material properties, produc-
tion of devices which combine microfabrication, microfluidics and
surface micropatterning techniques can be used to create a multi
compartment neuronal culture platform. This technology has po-
tential uses in a number of neuroscience applications including
studies of amyloid formation, where the ability to expose portions
of neurons to local insults is desired.114,115
Traditional approaches of cultivating neural cells without ori-
enting their interactions have had only a limited success in re-
vealing neural network properties. However, by combining the
concepts of micropatterned surfaces and microfluidic devices, var-
ious cell types, such as neurons and astrocytes, can be positioned
in defined locations, thus allowing the study of neuron-neuron
and neuron-astrocyte interactions under both healthy and patho-
physiological conditions, Fig. 6b.108 A similar approach was used
in the study of cell-cell interactions in neuroinflammation in the
context of neurodegenerative diseases. Different cell types were
plated in separate chambers of a microfluidic network and could
then be selectively primed with different stimuli. When chambers
are connected by microfluidic channels, the specific contributions
of the various cell types can be finely monitored by analysing their
morphologies, vitality, calcium ion dynamics, and electrophysio-
logical parameters.116
One set of central questions involves efforts to understand how
and why microglia accumulate in the vicinity of Aβ plaques.
Within microfluidic devices, microglial responses to gradients of
soluble Aβ can be maintained for weeks, and patterns of surface-
bound Aβ in microfluidic chemotaxis platforms have been quanti-
fied, Fig. 6c.110 This study demonstrates that soluble monomeric
and oligomeric Aβ can serve as a recruiting signal, while bound
fibrillar and oligomeric surface-bound Aβ acts as a targeting sig-
nal during microglia recruitment and localisation. Soluble and
insoluble Aβ have synergistic effects on microglial accumulation
to sites of Aβ deposits, and could explain microglial accumula-
tion in the vicinity of Aβ plaques in the cortex of those suffer-
ing from Alzheimer’s disease cortex. Using a microfluidic cham-
ber allowed CNS axons to be isolated in a compartment, where
molecules, such as brain-derived neurotrophic factor (BDNF),
could be selectively introduced. It was found in this study that
Aβ reduces BDNF signalling by impairing axonal transport and
this may underlie the dysfunction and loss of synapses observed
in Alzheimer’s disease.117 This study has recently been further ex-
panded to show that Aβ oligomers compromise BDNF-mediated
retrograde transport by impairing the velocities of endosomal
vesicles.118 Microfluidic strategies have further been developed
to perform sophisticated cell-based studies of amyloid formation.
Microsystems can provide an approach for presenting cells to con-
ditions in a controllable and reproducible fashion that cannot be
easily achieved by standard tissue culture methods, including ex-
posure to triggers, that vary in time and space, as well as to gra-
dients of molecules and secreted proteins from neighbouring cells
and physiological shear stresses from fluid flow.119
The contribution of cell-cell interactions can be studied by al-
lowing the communication of different brain cells through the dif-
fusion of soluble factors or through contact between specific cell
regions. Thus, cells in chips have been exposed to differently
aggregated forms of β -amyloid, mimicking an Alzheimer’s dis-
ease environment, and treated with CNS drugs in order to assess
the contribution of glial cells during pharmacological treatments.
In this context, the neurotoxicity of diffusible moieties was stud-
ied by regulating he surrounding microenvironments and creat-
ing a biomimetic microfluidic system generating spatial gradients
of diffusible oligomeric assemblies and assessing their effects on
cultured neuronal cells. It was found that although the number
of fibrils increased dramatically, the change in neurotoxicity with
time was small, suggesting that fibrils contribute little to neu-
rotoxicity. Moreover, exposure to Aβ was found to produce an
atrophy effect, and observed neurite extension during the differ-
entiation of neural progenitor cells increased when cells were cul-
tured under continuous flow.120 Such an approach may establish
a prospective microfluidic platform for studying the neurotoxicity
of Aβ and the potential neurotoxicity of oligomeric assemblies.
Such studies have mainly focused on the effects of soluble Aβ
species on cell-to-cell communication, but these approach can be
expanded further to study other amyloid-related protein systems.
Microfluidic cell culture chambers have been used recently to
study the uptake of different conformations of full-length human
tau in primary neurons, the mechanism by which they occur, and
the transport of tau aggregates within cultures of primary neu-
rons.109 It was shown that full-length tau readily aggregates into
low molecular weight species and fibrils, yet only certain aggre-
gates are internalised by neurons through bulk endocytosis. Addi-
tionally, aggregates from recombinantly expressed tau were found
to enhance tau pathology in vivo. Similarly, tau oligomers were
shown to be capable of entering human neurons and triggering
the formation of aggregated and hyperphosphorylated pathologi-
cal tau. These effects have been associated with long-term defects
in neurite outgrowth, synaptic and neuronal loss, abnormal neu-
rotransmission, and intracellular calcium ion mobilisation. These
findings provide molecular insights into observations from post-
mortem studies of human Alzheimer’s disease brains and mouse
models of propagation.121
Technological applications for amyloid struc-
tures
While the phenomenon of formation of aberrant protein self-
assembly has historically been studied in the context of its rel-
evance to human health, over the past decade significant efforts
have focused on utilising amyloid-like protein assemblies for the
development of functional biomaterials. Protein- and peptide-
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Fig. 7 Protein fibril microgel synthesis and their applications.
a) Schematic representation of protein microgel synthesis: (top)
water-in-oil microgels and oil-in-water microgel shells (bottom). The
corresponding 3D confocal images of microgel and microgel shell
particles stained with Nile Red are shown on the right-hand side of each
scheme. (b) The device design and experimental setup for processing
NSF into droplets (top), and examples of the various microgel
geometries achieved by modulating solution flow rates (bottom). 122
(c) Top left panel, droplet trapping device diagram showing the structure
of the droplet trapping device fabricated from PDMS with a schematic
diagram of enzymatic activity of trapped Ure2-AP microgel particles in
the droplet trapping device. 46 The substrate flows into the device by
hydrodynamic pumping and diffuses into the trapped Ure2-AP microgel
particles where it is efficiently converted into the product by the
fibril-displayed AP. Lower panel, observation of trapped Ure2-AP
microgel particles by bright-field DIC (far left). Fluorescence of the
substrate (blue) and product (green) after pumping the substrate into the
trapping device (middle panels). The three-dimensional microgel
particles and the fluorescence of the substrate and product were
reconstructed from serial two-dimensional scans by confocal
microscopy (far right). Scale bars are 20 µm 46.
based structural biopolymers are common building blocks for bi-
ological scaffold materials in nature, either in their native forms,
such as collagen, silk or fibronectin, or as related synthetic materi-
als.37–41,123 Such structures have inspired the production of self-
assembling materials, primarily via non-covalent cross-linking to
produce hydrogels as cell scaffolds by a large number of diverse
patterning techniques, utilising organic and polymeric materials,
including solvent-assisted micro-molding, micro-contact printing
and nanolithography, which form the basis of contemporary soft
lithography.124 Yet, such materials are limited in their ability to
provide an optimised environment for all cell types as the result-
ing scaffolds possess size scales and compositions which may or
may not promote cell viability.
Fibrous networks assembled by naturally derived peptides
and proteins offer unique opportunities for the production of
biomimetic cell culture platforms and implantable biomaterials
as they allow physiological cell-matrix interactions. While the
synthetic complexity of such systems can limit their applications,
amyloid fibril networks derived from common or readily avail-
able proteins such as lyzosyme with controllable topographies can
readily be designed and fabricated.125 In particular, the surface
chemistry of the fibrils has been shown to promote focal adhe-
sions of cultured cells, eliminating the need for complex protocols
for fibril decoration with bioactive moieties. The self-assembly
of proteins into amyloid fibrils on the nanoscale has been fur-
ther utilised as a micron-scale templating approach for droplet
microfluidic techniques to create a class of hierarchically ordered
functional materials. By utilising the aqueous phase separation
of dextran and polyethylene glycol (PEG) in a double T-junction
microfluidic device, a core-shell structure was produced through
the self-assembly of lysozyme into supramolecular structures that
could be tuned on the basis of changes in the in vitro environ-
ment such as pH and temperature.126 Furthermore, by employing
the intrinsic phase separation of dextran and PEG based aqueous
solutions, control over the selective partitioning of fibril-forming
protein molecules within each phase could be accomplished, giv-
ing rise to the formation and stabilisation of supramolecular core-
shell microgels with localised tunable properties. Such protein
nanofibrils can be used to form the basis of monodisperse mi-
crogels and gel shells with the potential to act as drug carrier
agents.45 These microfluidially produced particles have also been
demonstrated to enable the controllable release of four different
encapsulated drug-like small molecules, as well as the compo-
nent proteins themselves. Recently, hybrid organic/inorganic mi-
crocapsules containing metal-based nanoparticles and lysozyme
nanofibrils as a nanocomposite were produced by a microfluidic
droplet making device. In this study carboxyl-modified Fe3O4
nanoparticles were introduced into the lysozyme monomer or fib-
ril solutions and could functionalise the resulting fibrils, thus al-
lowing the production of nanofibril-inorganic nanoparticle micro-
capsules.127
Other self-assembling proteins have been explored in the con-
text of the search for control of material properties through the
application of microfluidic techniques. One recent example is the
use of spun silk for the production of ’micrococoons’ through mi-
crofluidic processing, Fig. 7b.122 Silk fibroin protein has been
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found to assemble into fibrils rich in β -sheet structures by a
combination of small-angle and wide-angle X-ray scattering and
Raman spectroscopy, revealing intrinsic similarities to amyloido-
genic proteins.128 The ability of fibroin to form ordered fibril-
lar structures has been employed as the basis for the production
of micron-scale capsules with controllable geometry and variable
levels of intermolecular β -sheet content in their protein shells.
These capsules have been shown to maintain the long-term sta-
bility of soluble monomeric proteins, which would otherwise be
prone to self-assembly in bulk solution. Moreover, the microco-
coons demonstrated effective encapsulation of other aggregation-
prone antibodies while allowing their storage and controlled re-
lease.122
Recently, microfluidic generation of enzymatically active micro-
gels that were stabilised by amyloid nanofibrils have been demon-
strated, Fig. 7c.46 The scaffolds formed by the prion domain of
Ure2 self-assembled under mild conditions and enabled the for-
mation of catalytic microgels while maintaining the integrity of
the encapsulated enzyme alkaline phosphatase. The enzymati-
cally active microgel particles exhibited further robust material
properties and their porous architecture allowed for the diffu-
sion of reactants and products. This approach has been further
implemented in droplet arrays, demonstrating their use as plat-
forms for enzyme immobilisation and recycling, as well as for
performing biological flow-chemistry. Moreover, along with util-
ising microfluidic-based techniques to maintain control over the
material properties and morphology of the capsules, the spectro-
scopic characterisation of specific species encapsulated within mi-
crodroplets has recently been demonstrated through the acqui-
sition of infrared spectra from single microdroplets containing
aggregation-prone proteins, such as lysozyme.78 Using this ap-
proach, structural differences in the amide bands of the spectra of
monomeric and aggregated lysozyme from single microdroplets
with picolitre volume could be resolved.
Outlook and conclusions
In this review we have discussed a wide range of microfluidic ap-
proaches for the study of amyloid formation, properties, and be-
haviour. Many of the techniques discussed have been reported as
proof-of-concept studies, but not yet adopted by the wider amy-
loid research community.129,130 The majority of the instruments
currently used to analyse proteins and protein self-assembly com-
plexes are bulky (e.g. mass-spectrometers) and operate over long
time-scales (e.g. chromatographic or gel-based protein purifi-
cation techniques combined with off line analysis techniques).
These features are in marked contrast to microfluidic techniques
which facilitate fast analysis on palm-sized chips. For the purpose
of most types of analysis these chips are operated in combination
with appropriate fluid handling and detection systems, although
paper and cloth microfluidics provide an exception to this re-
quirement.131,132 Translation of cutting edge microfluidic meth-
ods to applications in the life sciences is in many cases achieved
through collaboration between research groups in the physical
and life sciences.133 In addition, microfluidics-based technology
is introduced into non-specialist laboratories through commer-
cially available equiptment.134,135
Combining rapid analysis and small sample consumption with
the ability to control tightly the channel dimensions during fab-
rication, and the flow within these channels, microfluidic chips
present a still largely untapped potential to yield quantitative in-
formation about both individual proteins and the products formed
during their self-assembly process, including protein oligomers
and amyloid fibrils; thus for example, diffusional sizing analysis
has demonstrated equal or superior performance to conventional
dynamic light scattering setups.60,63 On-chip screening of the
electrophoretic mobilities of protein complexes has allowed de-
termination of binding curves and dissociation constants without
the biases that are often intrinsic to conventional surface-based
methods, such as surface plasmon resonance.64
We have explored how the physical properties of biomolecules
and supramolecular complexes can be quantified through the use
of microfluidic approaches, and furthermore how these param-
eters can be monitored to characterise molecular interactions.
Such assays show great promise in applications to improve our
understanding of the nature of amyloid species and how these
interact with cells and with potential inhibitors of the aggre-
gation process. In addition, microfluidic separation techniques
could provide a platform for sample purification from small vol-
umes. Although proof-of-concept experiments on separating a
small number of species on chip have been performed, microflu-
idic separation techniques are yet to become a routine approach
in biomolecular sciences.62,136 Notably, many of the interactions
occurring on the pathway of protein self-assembly into amyloid
fibrils and aggregates are not only transient, and hence accessi-
ble only to rapid analysis techniques, but also reversible and so
can potentially be affected by the presence of a matrix, such as
chromatography columns or acrylamide gel media, which further
emphasises the value of using solution phase based techniques
for their analysis, such as the aforementioned microfluidic ap-
proaches described here.
Intrinsic biomarkers have been exploited to sort cells in label-
free separation methods, including separation according to size,
shape, density, charge, deformability, and other properties of the
aggregating systems. The sorting of live and dead cells is criti-
cal to the diagnosis of the early stages of many conditions and to
test the efficacy of drugs. Micro-electromagnets are suitable for
the production of variable field gradients combined with differ-
ent channel designs, such as single wires and micro-coil arrays,
a microfluidic device containing integrated thermo-magnetically
patterned NdFeB films for cell separation using immunomagnetic
beads has been produced. This droplet based microfluidic ap-
proach allowed for high-throughput analysis of proteins released
from or secreted by cells, thereby overcoming one of the ma-
jor limitations of traditional flow cytometry and fluorescence-
activated cell sorting. This approach enables the dynamic recon-
figuration of the magnetic field patterns, but has the drawback
of generating Joule heating, which limits the maximum value of
the usable magnetic field considerably, and thus the field gradi-
ent that can be achieved; for example Joule heating may have
adverse effects on cell viability.137 In order to overcome these
limitations micro-patterning of permanent magnets within a solid
substrate upon which the microfluidic channel was placed were
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incorporated.138
The reduced volumes of microdroplets relative to conven-
tional microtiter plate assays make droplets an attractive platform
for high-throughput studies. Although the benefits of reduced
reagent consumption, faster assay time scale and parallelisation
have been demonstrated effectively for the analysis of a range
of assays, including those used for the study of protein aggre-
gation and neurodegenerative diseases, their extension to high-
throughput screening assays has so far been limited. This has
been partly due to the lack of effective barcoding techniques that
would enable successful candidates to be identified after the as-
says have been performed. Recently, barcoding of the genetic ma-
terial present in individual cells has been demonstrated through
the use of DNA-based barcode technology, which has led to a pro-
liferation of the studies in the field of single cell transcriptomics
and allowed the discovery of new cell types in blood and a num-
ber of tissues.139,140 The extension of such barcoding strategies
to molecules beyond the genetic material, for example to small
molecules that could serve as potential therapeutic compounds,
would open up the possibility of screening millions or even bil-
lions of compounds simultaneously, whilst consuming an amount
of sample that in non-droplet based methods would enable the
study of only a few dozen compounds. Such high throughput
screening assays have the potential to identify new therapeutic
molecules, which would be especially relevant for neurodegener-
ative disorders, such as Alzheimer’s and Parkinson’s diseases.
The presence of interfaces can influence the aggregation kinet-
ics for a wide range of proteins and peptides, for example, in the
case of Aβ aggregation, surface properties are of great importance
in modulating the aggregation process, leading to self-assembly at
concentrations that are many orders of magnitude below the criti-
cal aggregation concentration in bulk solution.141 Although it has
been generally recognised that the amyloid aggregation process
can be assisted or accelerated by surface chemistry142 and topog-
raphy, characterisation of the specific impact of different types of
surfaces and interfaces has been limited.141 The effect of surfaces
can be broadly divided into those arising from combinations of
three distinct interfaces, namely, solid, liquid and air interfaces.
Thus, the specific molecular surfaces found at the interface of cell
membranes can enhance the effective protein or peptide concen-
tration by specific binding or adsorption. As the effects of solid,
liquid and even air-water interfaces have mainly been studied un-
der bulk conditions, the increased availability of novel microflu-
idic approaches presents a potential means of studying surface in-
teractions.85,143–146 In particular, the use of microdroplet-based
techniques, where the properties of the interfaces encapsulating
solutions can be modulated easily, can allow for detailed analysis
of such effects.70
The well-defined flow properties within microfluidic channels
enable strategies to be developed to address questions, that would
be inaccessible to bulk solution methods. In this review, we
have discussed how the physical properties of biomolecules and
supramolecular complexes, particularly in the context of amy-
loid formation can be defined through the use of microfluidic
approaches and furthermore how these parameters can be mon-
itored to characterise specific interactions. Such assays have
shown great promise in applications to improve our understand-
ing of the nature of amyloid species and how these interact with
potential inhibitors of protein aggregation. We have discussed
above some of the applications of amyloid structures as novel ma-
terials and cases where microfluidic methods have already been
integrated into the production of materials. Indeed, the use of
amyloid structures as scaffolds and in smart materials is an ex-
panding field, with applications emerging in water purification,
nutrient delivery, and in the production of composite materi-
als.130,147,148 The use of microfluidic strategies to explore the
potential of amyloid-based materials is therefore set to increase
substantially. Microfluidic methods have been applied to study
a large number of aspects of amyloid formation and behaviour.
With the continuous development and adaptation of these tech-
niques, there is the potential for such strategies to play an even
larger role in the rapidly developing field of amyloid research.
The number of individuals affected by amyloid disorders is set
to increase over the coming years, resulting in a devastating im-
pact on society and a great demand on resources. Developing a
detailed understanding of the formation and behaviour of amy-
loid structures is therefore a pertinent objective.6 In addition
to the impetus of disease association to amyloid research, amy-
loid structures are showing a considerable potential as a basis
for smart and active materials.While microfluidic approaches are
constantly developed and optimised in the context of chip design,
translation of such techniques now bridges the gap between fun-
damental physicochemical studies and a clearer understanding
of natural processes while further implementation of these tech-
niques are now progressing to large scale production.
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